News
-
EMA publishes a reflection paper on AI in medicinal product lifecycle
The European Medicines Agency has recently published a reflection paper on the integration of artificial intelligence (AI)
throughout the lifecycle of medicinal products.
-Read more-
-
Network strategy to 2028: public consultation
The draft European Medicines Agencies Network Strategy to 2028 is available for public consultation. The deadline to comment is 30 November 2024.
-Read more-
-
Speeding up Duchenne Muscular Dystrophy therapies with a model-based clinical trial simulator
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder causing muscle deterioration. Despite advances, no cure exists, and current treatments only slow progression. To support drug development, the FDA’s Critical Path Initiative and C-Path’s Duchenne Regulatory Science Consortium (D-RSC) launched a clinical trial simulation tool. This tool optimizes trials, supporting regulatory approval and speeding new therapies to market.
-Read more-
-
PhD and postdoc opportunities - October 2024
New calls with deadlines end October - early November
-Read more-
-
Are you a clinician? Fill out the survey to share your familiarity & level of adoption of in silico medicine!
In 2021, the Virtual Physiological Human Institute conducted a clinical survey among clinicians to collect feedback regarding their knowledge, experience, and opinions about CM&S in the clinical practice. Now VPHi is realising a second and much larger survey aiming at involving doctors worldwide.
-Read more-
-
Survey on Mechanical data from biological tissues
The survey aims to gather insights on the priorities and interests related to mechanical data from various tissue types and population demographics.
-Read more-
